Enanta Pharmaceuticals Downgraded by JMP Securities to “Market Perform” (ENTA)
Enanta Pharmaceuticals (NASDAQ:ENTA) was downgraded by investment analysts at JMP Securities from an “outperform” rating to a “market perform” rating in a note issued to investors on Monday, TheFlyOnTheWall.com reports.
The analysts wrote, “market outperform” to “market perform”
ENTA has been the subject of a number of other recent research reports. Analysts at Robert W. Baird downgraded shares of Enanta Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Tuesday, June 24th. They now have a $41.00 price target on the stock. They noted that the move was a valuation call. Analysts at Zacks upgraded shares of Enanta Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Wednesday, April 16th. They now have a $43.80 price target on the stock. Two investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. Enanta Pharmaceuticals presently has an average rating of “Hold” and an average target price of $43.20.
Enanta Pharmaceuticals (NASDAQ:ENTA) opened at 42.75 on Monday. Enanta Pharmaceuticals has a one year low of $16.85 and a one year high of $46.443. The stock’s 50-day moving average is $40.72 and its 200-day moving average is $36.72. The company’s market cap is $792.5 million.
Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.69 by $0.97. The company had revenue of $2.20 million for the quarter, compared to the consensus estimate of $1.20 million. On average, analysts predict that Enanta Pharmaceuticals will post $0.69 earnings per share for the current fiscal year.
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses its chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.